Investigation of Sulindac in Male Fragile X Syndrome Patients Aged 13-40
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is to investigate the safety, tolerability and efficacy of Sulindac in males with
Fragile X Syndrome (FXS) with confirmed full FMR1 mutation treated over a 10 week period in
an outpatient setting.